… In summary, this study demonstrated that both gefitinib and erlotinib showed … line treatment
for selected population of NSCLC. Further study with inclusion of both gefitinib and erlotinib in …

… in the gefitinib and 17% in the erlotinib group discontinued therapy due to … treatment were,
respectively, 2.8 and 7.6 months in the erlotinib group, and 2.4 and 5.0 months in the gefitinib …

… efficacy than gefitinib or erlotinib in first-line treatment of EGFR-… effective than erlotinib as
second-line treatment of patients with … studies, with emphasis on comparability between gefitinib …

… factor receptor, gefitinib and erlotinib, have changed the treatment paradigm of advanced
non-… Many phase II or III studies have proven the efficacy of gefitinib or erlotinib as the first-line, …

… The present study analyzed experiences in treating a large population of NSCLC patients
with gefitinib and erlotinib in order to reveal the trend on drug selection between the two TK …

… DISCUSSION In this matched-pair case-control study, we demonstrated that gefitinib and
erlotinib … Also, in this study, patients were treated with 250mg/d of gefitinib, and there was no …

… study showed that erlotinib and gefitinib had similar effectiveness but gefitinib had a better
safety profile compared to erlotinib… erlotinib and gefitinib for treating NSCLC in our study …

… A number of Lung Disease Site Group members, including two of the lead authors of this
systematic review, have been research investigators on clinical trials of gefitinib or erlotinib, …

… This study investigated maintenance gemcitabine or erlotinib versus observation, following
… demonstrate that maintenance therapy with EGFR TKIs (gefitinib and erlotinib) produces a …

… Treatment schedule … at a 1 : 1 ratio to receive oral erlotinib 150 mg or gefitinib 250 mg once
daily. Second- and further-line treatments were defined as second line in the present study. …